Today we shared positive Phase 2b results evaluating our investigational anti-TL1A biologic in adults with moderate to severe hidradenitis suppurativa (HS). Learn more: go.merck.com/~73c

Learn more about our latest update in #oncology: go.merck.com/~oolz4s

In collaboration with @EisaiUS, we’re proud to announce today’s #FDA approval of a new combination treatment option for certain patients with advanced renal cell carcinoma, marking an important step forward for people living with #KidneyCancer. Learn more: go.merck.com/~nex

Today, we announced Phase 2b/3 topline results for our investigational therapy in patients with #DiabeticMacularEdema (DME). This important milestone reflects our ongoing commitment to advancing research in #ophthalmology. Learn more: go.merck.com/~k7a

Today, the FDA approved an updated label for a treatment option for adults living with pulmonary arterial hypertension (#PAH). Read more: go.merck.com/~c9i

Learn more about our latest update in #oncology: go.merck.com/~yhzw

Today, we announced a positive CHMP opinion for a combination treatment regimen for adults with resectable muscle-invasive #BladderCancer (MIBC) in the European Union. Read more: go.merck.com/o918

In collaboration with @moderna_tx, we’re excited to share the first positive Phase 3 topline results for our investigational individualized neoantigen therapy (INT) in combination with our company’s immunotherapy in the adjuvant setting for certain patients with completely resected stage IIB-IV #melanoma: go.merck.com/~819

We’re pleased to announce the FDA has accepted our filing related to #RSV disease. Learn more: go.merck.com/~dti

Join us today at 9 a.m. ET to learn more about our Q2 2026 #earnings: go.merck.com/~ea2 $MRK

Our Q2 2026 #earnings results are live: go.merck.com/~2q6 Swipe below for perspective from Chairman and CEO Rob Davis. $MRK

Today we announced our initial post-approval access plans for our investigational HIV pre-exposure prophylaxis (PrEP). We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can quickly reach those who need it in low- and middle-income countries. Learn more: go.merck.com/~5hd

We’re presenting new data at AIDS 2026, in collaboration with @GileadSciences, from our Phase 3 trials of an investigational, once-weekly oral #HIV treatment for adults with virologically suppressed HIV. Learn more: go.merck.com/~lkm

Today, we’re proud to announce the U.S. FDA approved the first oral PCSK9 inhibitor, providing a new treatment option as an adjunct to diet and exercise for adults living with #hypercholesterolemia, or high LDL cholesterol (LDL-C). Learn more about our approval here: go.merck.com/~usf

We’re excited to join the global HIV community at AIDS2026 to share new #HIV research. Learn more: go.merck.com/~a48

Today, we shared positive Phase 3 topline results in certain patients with advanced or recurrent #EndometrialCancer. These findings mark an important step forward as we work to advance new treatment options for these patients. Learn more: go.merck.com/~ja6

Today, we announced the #FDA has approved two new treatments for certain patients with muscle-invasive #BladderCancer, expanding options for these patients. Learn more: go.merck.com/~app

Today, we announced an agreement with the AIDS Crisis Task Force to provide increased access to #HIV treatment for eligible people living with HIV through state AIDS Drug Assistance Programs (ADAPs). Learn more: go.merck.com/~8le

We’re proud to announce the #FDA approvals of two new immunotherapy-based treatment combinations for certain adults with advanced triple negative breast cancer (#TNBC). This milestone, in collaboration with @GileadSciences, is an important step forward in care for patients with this disease. Learn more: go.merck.com/~y66

Today, the European Commission approved a new treatment combination for certain patients with muscle-invasive #BladderCancer (MIBC). Together with Pfizer and Astellas Pharma, we’re proud to provide a treatment poised to address an important unmet need for these patients. Learn more: go.merck.com/~1li